Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.
about
Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antiviralsEmerging therapies for hepatitis CTelaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients.Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosisDirect-acting antivirals for chronic hepatitis C.Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies.Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictorsEvaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study.Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: the Optim study.Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience.Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities.Serotonin and its implication in the side-effects of interferon-based treatment of patients with chronic viral hepatitis: Pharmacological interventions.The pharmacokinetic evaluation of boceprevir for treatment of hepatitis C virus.Management of HCV patients with cirrhosis with direct acting antivirals.Advances in and the future of treatments for hepatitis C.Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy.Treatment discontinuation with peg-interferon: what to consider.Impaired interferon signaling in chronic hepatitis C patients with advanced fibrosis via the transforming growth factor beta signaling pathway.Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program.Boceprevir in liver transplant recipients.Serum 25-hydroxyvitamin D3 levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load.KASL clinical practice guidelines: management of hepatitis C.Regulation of interferon signaling and HCV‑RNA replication by extracellular matrix.Direct-acting antivirals for chronic hepatitis C
P2860
Q26782033-7FB52F51-F1A2-4A0F-80BA-9DBBE6076DABQ26853642-4F592BA0-7249-428F-86A1-8842C051AE2BQ30430083-24F000A5-88C5-4748-B5B4-313762FB7372Q30620900-3C9FC049-82F8-47E0-8600-22B2484CE37CQ33425278-B4C52203-AE1D-4FB0-BD68-48E0528B1781Q34557595-F34CDBFE-D662-415A-B2DF-AA3062AC44B1Q34571043-3D216F7E-0C8D-4032-BB05-8FE73559CFFFQ34589830-C3BFF133-6DAC-40D2-A4FA-C9DA96DCA3ADQ35146790-0FF164F5-FB1E-4E7A-8C92-BFCE5D7E8584Q35169370-D28CBBBE-8564-4DF9-B319-7B56979AD900Q35591160-C81DB2F5-1D4F-4E0D-BBFD-D7E905FFABB1Q35785198-63E561A3-0689-4EE3-BA8C-F3170650DC0EQ37157057-55D48909-C9D1-491A-B927-50198CF8165DQ37678082-8A829BE0-D5D8-4861-AF58-F868996AE19CQ38100813-A9C209AD-E28E-4611-A607-01137D6B20A8Q38147375-C2623B7E-170E-45B0-9E34-CABFA76232B0Q38174248-AFA1901D-A04C-412A-A974-E4B0005D6A59Q38213321-1926A1A9-E75C-4523-AB74-4C25462EDF69Q38458110-6CCEB0BD-1F6F-472E-99FB-741424A55C0CQ38599378-7E82D369-E940-4F5F-B311-863EB57C3AFFQ38981552-69B0FFC2-F8BC-4C2E-935E-3481AA3C77FAQ40787997-23333F73-F750-4E06-8092-3A7281A10686Q41703167-163DFCD4-62A9-4DA4-8625-1BEE394AAD3AQ42228721-8ED01981-5BBD-4516-A270-2BF3F3F9A071Q42243719-7062C83E-9518-4642-A4E3-6722CF4A81C7Q51836024-6901C3FC-144E-41A9-ADDD-CFF819C3B879Q54203070-93370AE6-472D-4E76-8DA7-6C3798AD6373Q57389418-945567D1-8D90-4CF1-8FDB-38D59F8C869A
P2860
Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Efficacy and safety of bocepre ...... d advanced fibrosis/cirrhosis.
@ast
Efficacy and safety of bocepre ...... d advanced fibrosis/cirrhosis.
@en
type
label
Efficacy and safety of bocepre ...... d advanced fibrosis/cirrhosis.
@ast
Efficacy and safety of bocepre ...... d advanced fibrosis/cirrhosis.
@en
prefLabel
Efficacy and safety of bocepre ...... d advanced fibrosis/cirrhosis.
@ast
Efficacy and safety of bocepre ...... d advanced fibrosis/cirrhosis.
@en
P2093
P50
P1476
Efficacy and safety of bocepre ...... d advanced fibrosis/cirrhosis.
@en
P2093
Bruce Bacon
Clifford A Brass
Hugo Tanno
Janice K Albrecht
John M Vierling
Keith Gottesdiener
Lisa D Pedicone
Lisa M Nyberg
Margaret H Burroughs
Seth Thompson
P304
P356
10.1016/J.JHEP.2012.11.020
P577
2012-11-23T00:00:00Z